RT Journal Article
SR Electronic
T1 Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 869
OP 872
DO 10.2967/jnumed.122.264946
VO 64
IS 6
A1 Gudenkauf, Lisa M.
A1 Chavez, Melody N.
A1 Maconi, Melinda Leigh
A1 Geiss, Carley
A1 Seyedroudbari, Ameen
A1 Thin, Pan
A1 Hoogland, Aasha I.
A1 Nguyen, Kathleen
A1 Murthy, Vishnu
A1 Armstrong, Wesley R.
A1 Komrokji, Khaled
A1 Oswald, Laura B.
A1 Jim, Heather S.L.
A1 El-Haddad, Ghassan
A1 Fendler, Wolfgang P.
A1 Herrmann, Ken
A1 Cella, David
A1 Czernin, Johannes
A1 Hofman, Michael S.
A1 Dicker, Adam P.
A1 Calais, Jeremie
A1 Tagawa, Scott T.
A1 Gonzalez, Brian D.
YR 2023
UL http://jnm.snmjournals.org/content/64/6/869.abstract
AB The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first 177Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patients receiving RNT. Methods: We identified relevant symptoms and toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the Functional Assessment of Cancer Therapy–Radionuclide Therapy (FACT-RNT) with patient input. Results: This multistep process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The FACT-RNT is a new standardized tool to monitor relevant symptoms and toxicities among PC patients in RNT trials and real-world settings.